Phase 1b Study of CAR2Anti-CEA CAR-T Cell Hepatic Infusions for Pancreatic Carcinoma Patients With CEA+ Liver Metastases

Metastatic Pancreatic Carcinoma Clinical Trial

— AntiCEA_CART  

Official title:

Phase 1b Study of the Efficacy and Safety of CAR2 Anti-CEA CAR-T Cell Hepatic Infusions for Pancreatic Carcinoma Patients With CEA+ Liver Metastases Resistant to Standard Therapy Using the HITM Method and Pressure Enabled Delivery Device

Clinical Trial Details — Status: Terminated

Administrative data

• NCT number: NCT03818165
• Other study ID #: SOR-CART-CEA-001
• Status: Terminated
• Phase: Phase 1
• Start date: July 29, 2019
• Est. completion date: May 21, 2021

Study information

• Verified date: January 2023
• Source: Sorrento Therapeutics, Inc.
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This study is an open-label, single arm phase 1b safety study of CAR2 Anti-CEA CAR-T cell hepatic arterial infusions for pancreatic carcinoma patients with carcinoembryonic antigen positive (CEA+) liver metastases resistant to standard therapy who meet all other eligibility criteria.

Description:

Patients will receive weekly 3 doses of CAR2 Anti-CEA CAR-T cells in each 28-day cycle by hepatic arterial infusions using a Pressure Enhanced Delivery Device (PEDD) with low dose systemic IL-2 support. Patients may receive up to 3 cycles of CAR2 Anti-CEA CAR-T cell hepatic arterial infusions, per discretion of the investigator.

All patients who receive investigational CAR-T therapy will be included in the analyses and summaries of safety, efficacy, pharmacokinetic, and pharmacodynamic assessments.

Recruitment information / eligibility

• Status: Terminated
• Enrollment: 2
• Est. completion date: May 21, 2021
• Est. primary completion date: January 19, 2020
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Must have documented CEA+ pancreatic adenocarcinoma liver metastases and have failed greater than or equal to 1 line of conventional systemic therapy.

• Must have at least evaluable liver metastases.

• Must have a life-expectancy at least 12 weeks.

• Patients must be willing and able to comply with the study schedule and all other protocol requirements.

• Females of childbearing potential must have 2 negative pregnancy tests, agree to pregnancy tests during the study, and sexually active female and male patients must be willing to use an effective birth control method to avoid pregnancy.

Exclusion Criteria:

• Subjects who have received an investigational study drug within 14 days of leukapheresis or 28 days before receiving first dose of study drug.

• Subjects who have received any approved anticancer medication within 14 days of leukapheresis or 14 days before receiving the first dose of study drug.

• Have any unresolved toxicity greater than Grade 2 from previous anticancer therapy.

• Have a history of confirmed metastases outside the peritoneal cavity, lungs, or liver.

• More than 50% replacement of one or both liver lobes with tumor.

• Has tumor causing biliary obstruction not amenable to stenting.

• Have a high volume of lung or peritoneal metastases.

• Has received any CAR cell line therapies.

• Has any clinically significant low baseline lab results for hemoglobin, platelet counts, and neutrophil counts at screening.

• Has untreated or ongoing intra-abdominal infection or bowel obstruction.

• Has any clinically significant elevated baseline lab results for serum creatinine, AST, and total bilirubin (except for patients in whom hyperbilirubinemia is attributed to Gilbert's syndrome), and alkaline phosphatase at screening regardless of causality.

• Known HIV or acquired immunodeficiency syndrome-related illness, acute or history of chronic hepatitis B or C.

• Female patients who are pregnant or breastfeeding.

• Have active bacterial, viral, or fungal infections.

• Has any significant medical condition, laboratory abnormality, or psychiatric illness that would prevent study participation.

• Left ventricular ejection fraction (LVEF) < 40%.

Related Conditions & MeSH terms

• Carcinoma
• Metastatic Pancreatic Carcinoma
• Neoplasm Metastasis
• Pancreatic Neoplasms

Intervention

Biological:
• CAR2 Anti-CEA CAR-T cells
doses will be delivered by hepatic arterial infusions using pressure enhanced delivery device (PEDD)

Locations

Country	Name	City	State
United States	Roger Williams Medical Center	Providence	Rhode Island

Sponsors (1)

Lead Sponsor	Collaborator
Sorrento Therapeutics, Inc.

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Other	Assess if serum cytokine levels correlate with response and/or toxicity to hepatic arterial infusions.	As an exploratory analysis, serum cytokine levels will be measured by ELISA to determine if increases in cytokines predict response and/or toxicity to liver arterial infusions.	6 months
Other	Assess if neutrophil:lymphocyte ratios correlate with response	As an exploratory analysis, neutrophil:lymphcyte ratios will be calculated to determine if they correlate with response and/or toxicity.	6 months
Other	Assess the persistence of CAR-T cells circulating in blood over time	As an exploratory analysis, circulating CAR-T cells will be analyzed to assess persistence of CAR-T cells during the treatment and observation phases of the study.	6 months
Other	Assess the persistence of CAR-T cells in liver tumor biopsies over time	As an exploratory analysis, the engraftment of CAR-T cells in planned liver tumor biopsies will be analyzed to assess persistence of CAR-T cells during the treatment and observation phases of the study.	6 months
Other	Assess if circulating tumor cells (CTC) correlate with response	As an exploratory analysis, levels of circulating tumor cells (CTC) will be determined to investigate if decreases in CTC levels correlate with response.	6 months
Primary	Assess preliminary efficacy by overall survival	As a measure of activity, Overall Survival (OS) will be assessed. The events for the assessment of OS are death events. Time to event endpoints will be estimated using Kaplan-Meier methods. Point estimates and 95% confidence intervals will be provided where applicable.	6 months
Secondary	Assess preliminary efficacy by radiographic response rate using Response Evaluation Criteria in Solid Tumors (RECIST)	As a measure of activity, overall response rate will be assessed by radiographic scans using RECIST criteria. Response will be assessed for each patient over a 6-month timeframe during the treatment and observation phases of the protocol.	6 months
Secondary	Assess preliminary efficacy by metabolic response rate using PET Response Criteria in Solid Tumors (PERCIST)	As a measure of activity, overall response rate will be assessed by radiographic scans using PERCIST criteria. Response will be assessed for each patient over a 6-month timeframe during the treatment and observation phases of the protocol.	6 months
Secondary	Assess preliminary efficacy by response rate using Immune-related Response Criteria (irRC)	As a measure of activity, overall response rate will be assessed by radiographic scans using irRC. Response will be assessed for each patient over a 6-month timeframe during the treatment and observation phases of the protocol.	6 months
Secondary	Assess preliminary efficacy by histologic response rate using pathologic response in biopsy specimens	As a measure of activity, overall response rate will be assessed by pathologic criteria using biopsies of the liver metastases and measuring necrosis and fibrosis. REsponse rates will be assess for each patient over a 6-month timeframe during the treatment and observation phases of the protocol.	6 months
Secondary	Assess preliminary efficacy by serologic response rates by CEA levels	As a measure of activity, overall response rate will be assessed by serologic CEA levels. Response will be assess for each patient over a 6-month timeframe during the treatment and observation phases of the protocol.	6 months
Secondary	Assess preliminary efficacy by serologic response rates by CA 19-9 levels	As a measure of activity, overall response rate will be assessed by serologic CA 19-9 levels. Response will be assess for each patient over a 6-month timeframe during the treatment and observation phases of the protocol.	6 months
Secondary	Assess preliminary efficacy by duration of response in accordance with RECIST criteria	As a measure of activity, duration of response will be measured using radiologic scans and assessed according to RECIST criteria. This will be assess for each patient over a 6-month timeframe during the treatment and observation phases of the protocol.	6 months
Secondary	Assess preliminary efficacy by in-liver progression free survival (PFS)	As a measure of activity, in-liver PFS will be assessed. The events for the assessment of PFS are disease progression and death events. This time to event endpoint will be estimated using Kaplan-Meier methods. Point estimate estimates and 95% confidence intervals will be provided where appropriate.	6 months